Abstract Number: 2231 • 2018 ACR/ARHP Annual Meeting
An Ancestral-Specific Interaction of TRIM46 with a Past-History of Smoking May Influence Gout Risk
Background/Purpose: Gout is caused by an interplay of genetic and environmental factors. Epidemiological and prospective studies suggest that current-smoking may be protective for developing gout…Abstract Number: 2232 • 2018 ACR/ARHP Annual Meeting
Prevalence of Gout in the Surviving U.S. Solid Organ Transplant Population
Background/Purpose: Although incidence and survival are frequent topics within the solid organ transplant (SOT) literature, there are no recent publications on the total size of…Abstract Number: 2233 • 2018 ACR/ARHP Annual Meeting
Activation and Deficiency of Circulating Mucosal-Associated Invariant T Cells in Patients with Gouty Arthritis
Background/Purpose: Mucosal-associated invariant T (MAIT) cells contribute to protection against certain microorganism infections and play an important role in mucosal immunity. Upon antigen recognition, MAIT…Abstract Number: 2234 • 2018 ACR/ARHP Annual Meeting
Liver Safety of Febuxostat Compared with Allopurinol in Gout Patients with Fatty Liver Disease
Background/Purpose: Although febuxostat has been widely used for lowering uric acid levels because of its renal safety compared with allopurinol, data on the hepatic safety…Abstract Number: 2235 • 2018 ACR/ARHP Annual Meeting
Monosodium Urate Deposition Distribution in the Knees, Hands, and Feet of Treated Gout Patients: A Dual-Energy CT Study
Background/Purpose: Prior studies have demonstrated that monosodium urate (MSU) deposits on dual-energy CT (DECT) are commonly found in joints as well as tendons of the…Abstract Number: 2236 • 2018 ACR/ARHP Annual Meeting
Contemporary Comorbidity Burden of Gout and Hyperuricemia in the US during the Past Decade (National Health And Nutrition Examination Survey [NHANES] 2007-2016)
Background/Purpose: Precise estimates of the comorbidity burden of gout and hyperuricemia are critical as their presence has important implications for the treatment of both gout…Abstract Number: 2237 • 2018 ACR/ARHP Annual Meeting
Prevalence of Urate-Lowering Therapy Use and Target Urate Level Achievement Among Gout Patients in the United States (National Health And Nutrition Examination Survey [NHANES] 2007-2014)
Background/Purpose: To determine the latest national prevalence of urate-lowering therapy (ULT) use and achievement of a therapeutic target serum urate level (SUL) in gout patients,…Abstract Number: 2238 • 2018 ACR/ARHP Annual Meeting
Non-Coding Urate-Associated Variants Function in a Conserved Lincrna Regulatory Domain That Alters MAF transcription
Background/Purpose: Genome-wide association studies (GWAS) have revealed that the large majority of disease-associated single nucleotide polymorphisms (SNPs) are located in the non-coding regions of the…Abstract Number: 2239 • 2018 ACR/ARHP Annual Meeting
Tenocytes Extracted from Rotator Cuff Tendons Are Able to Induce Mineral Deposition in Vitro and Express Genes Related to a Chondrocyte Differentiation
Background/Purpose: Calcific tendonitis is a frequent cause of shoulder pain. The calcium deposits are composed of carbonated apatite and their origin stays still largely unknown.…Abstract Number: 2240 • 2018 ACR/ARHP Annual Meeting
Hip Involvement in Patients with Gout: Results of an Ultrasound Study
Background/Purpose: Although considered as uncommon, the hip represents one of the possible targets of gout. To date, hip involvement in patients with gout has been…Abstract Number: 2241 • 2018 ACR/ARHP Annual Meeting
What Can Variation in Clinical Practice Teach Us about Treatment Strategies for Patients with Gout?
Background/Purpose: To improve quality of care for patients with gout, two hospitals in the Netherlands initiated a protocolized gout clinic. One clinic adopted a patient-centred…Abstract Number: 2242 • 2018 ACR/ARHP Annual Meeting
Cardiovascular Outcomes of Treatment with Febuxostat and Allopurinol in Gout Patients with Kidney Disease
Background/Purpose: The Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Comorbidities (CARES) trial demonstrated that major cardiovascular (CV) outcomes on febuxostat…Abstract Number: 2243 • 2018 ACR/ARHP Annual Meeting
Sex Difference of the Association between Serum Urate and Blood Pressure in Young Adults
Background/Purpose: Serum urate (sUA) has been associated with blood pressure in most but not all studies. This study aims to test whether there are sex…Abstract Number: 2244 • 2018 ACR/ARHP Annual Meeting
Comparison of an Interactive Voice Response (IVR) to Smart Phone App to Determine Patient Preference for Reporting Gout Flares
Background/Purpose: Gout flares are a major cause of morbidity and are an important outcome in clinical studies. Significant limitations for timely flare ascertainment exist, and…Abstract Number: 2245 • 2018 ACR/ARHP Annual Meeting
Lubricin/Proteoglycan 4 (PRG4) Inhibits NLRP3 Inflammasome Assembly in Monosodium Urate (MSU)-Crystal Induced Arthritis.
Background/Purpose: Lubricin/proteoglycan-4 (PRG4) is a mucinous glycoprotein secreted by synovial fibroblast and superficial zone chondrocytes. PRG4 has a multifaceted homeostatic role in the joint including…
